Announcements Trials
Browse Landscape

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 98Observational 4Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 2

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × ibrutinib × Clear all
NCT06299540 2026-05-08

QOLIBRI

Janssen Cilag S.A.S.

Recruiting
180 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03476655 2025-02-03

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Johnson & Johnson Private Limited

Completed
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03425591 2022-10-06

FIRE

Janssen-Cilag Ltd.

Completed
508 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03720561 2022-01-03

EVIdeNCE

Janssen-Cilag S.p.A.

Completed
312 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡